Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
All content for On The Pen With Dave Knapp is the property of Bleav, Dave Knapp Founder of On The Pen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
GLP-1 Microdosing For Weight Loss: Noom CEO Explains Their New Program
On The Pen With Dave Knapp
42 minutes 22 seconds
2 months ago
GLP-1 Microdosing For Weight Loss: Noom CEO Explains Their New Program
GLP-1 microdosing is one of the hottest and most controversial topics in obesity medicine right now. Can lowering your dose instead of quitting completely help you keep the weight off? In this exclusive interview, Noom CEO Geoff Cook responds to questions about microdosing, GLP-1 off-ramping, and how Noom supports patients using medications like Mounjaro, Zepbound, Wegovy, and Ozempic.
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
